Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea

Clinical Infectious Diseases

Volumn 43, Issue 4, 2006, Pages 411-420

  Louie, Thomas J ^a,l   Peppe, Jennifer ^e   Watt, C Kevin ^f   Johnson, David ^g   Mohammed, Rasheed ^k   Dow, Gordon ^b   Weiss, Karl ^c   Simon, Stuart ^h,i   John Jr , Joseph F ^j   Garber, Gary ^d   Chasan Taber, Scott ^e   Davidson, David U ^e  

^a UNIVERSITY OF CALGARY   (Canada)

^b MONCTON HOSPITAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e GENZYME CORPORATION   (United States)

^f Bio Test Clinic   (United States)

^g Bay Pines VA Medical Center   (United States)

^h RADIANT RESEARCH   (United States)

ⁱ Georgia Lung Associates   (United States)

^j RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^k AIREDALE GENERAL HOSPITAL   (United Kingdom)

^l FOOTHILLS HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; POLYMER; POLYSTYRENE DERIVATIVE; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DISSEMINATED CANCER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPOKALEMIA; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RESPIRATORY FAILURE; SEPTIC SHOCK; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; DIARRHEA; DOUBLE-BLIND METHOD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FEMALE; HUMANS; IONS; MALE; MIDDLE AGED; POLYMERS; POLYSTYRENES; VANCOMYCIN;

EID: 33746656237     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/506349     Document Type: Article

References (35)

1. Hogenauer C, Hammer HF, Krejs GJ, et al. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998; 27: 702-10.
2. Yamamoto-Osaki T, Kamiya S, Sawamura S, et al. Growth inhibition of Clostridium difficile by intestinal flora of infant faeces in continuous flow culture. J Med Microbiol 1994; 40:179-87.
3. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257-62.
4. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response and toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001; 357:189-93.
5. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62:384-9.
6. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991-2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
7. National Clostridium difficile Standards Group: report to the Department of Health. J Hosp Infect 2004; 56(Suppl 1):1-38.
8. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004; 189:1585-9.
9. Buchner AM, Sonnenberg A. Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci 2002; 47:201-7.
10. Health Protection Agency. Voluntary reporting of Clostridium difficile, England, Wales and Northern Ireland: 2004. Commun Dis Rep CDR Wkly 2005; 15:1-3. Available at: http://www.hpa.org.uk/cdr/archives/2005/cdr2005.pdf. Accessed 2 July 2006.
11. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
12. Institut National de Sante Publique. La surveillance des diarrhees associees aux infections a Clostridium difficile: deuxieme rapport tire du systeme de surveillance des infections a Clostridium difficile (SSICD) de l' Institut National de Sante Publique du Quebec [in French]. Available at: http://www.inspq.qc.ca/pdf/publications/370-ResultatsCDifficile-22Aout2004- 05Fevrier2005.pdf. Accessed 2 July 2006.
13. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hyper virulent strain in Quebec. CMAJ 2005; 173:1037-41.
14. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
15. Bartlett JG. Management of Clostridium difficile infection and other antibiotic-associated diarrhoeas. Eur J Gastroenterol Hepatol 1996; 8: 1054-61.
16. Butterworth SA, Koppert E, Clarke A, et al. Recent trends in diagnosis and treatment of Clostridium difficile in a tertiary care facility. Am J Surg 1998; 175:403-7.
17. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:1027-34; quiz 35-6.
18. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269:71-5.
19. Pothoulakis C, LaMont JT. Clostridium difficile colitis and diarrhea. Gastroenterol Clin North Am 1993; 22:623-37.
20. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92:739-50.
21. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec Canada. Clin Infect Dis 2005; 40:1591-7.
22. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of C. difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.
23. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001; 45:2340-7.
24. Braunlin W, Xu Q, Hook P, et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 2004; 87:534-9.
25. Chow SC, Shao J, Wang H. Sample size calculations in clinical research. New York: Marcel Dekker, 2003.
26. Davidson D, Porzio A, Nealon P, Peppe J. A randomized, double-blind, placebo-controlled, parallel design trial of multiple doses of tolevamer in healthy male volunteers [poster 1579]. In: Program and abstracts of the 15th European Congress of Clinical Microbiology and Infectious Diseases (Copenhagen, Denmark). 2005.
27. Fekety R, Silva J, Buggy B, Derry HG. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother 1984; 14(Suppl D): 97-102.
28. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86:15-9.
29. Yassin SF, Young-Fadok TM, Zein NN, et al. Clostridium difficile-associated diarrhea and colitis. Mayo Clin Proc 2001; 76:725-30.
30. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997; 25(Suppl 2):S206-10.
31. Roe FJ. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic and teratogenic potential. Surgery 1983; 93:158-64.
32. Urtasun RC, Rabin HR, Partington J. Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously. Surgery 1983; 93:145-8.
33. Marshall DA, Hunter JA, Capell HA. Double-blind, placebo controlled study of metronidazole as a disease modifying agent in the treatment of rheumatoid arthritis. Ann Rheum Dis 1992; 51:758-60.
34. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc 1999; 74:825-33.
35. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile-associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-84.